PT - JOURNAL ARTICLE AU - Rajagopal, Veera M. AU - Duan, Jinjie AU - Vilar-Ribó, Laura AU - Grove, Jakob AU - Zayats, Tetyana AU - Ramos-Quiroga, J. Antoni AU - Satterstrom, F. Kyle AU - Soler Artigas, María AU - Bybjerg-Grauholm, Jonas AU - Bækvad-Hansen, Marie AU - Als, Thomas D. AU - Rosengren, Anders AU - Daly, Mark J. AU - Neale, Benjamin M. AU - Nordentoft, Merete AU - Werge, Thomas AU - Mors, Ole AU - Hougaard, David M. AU - Mortensen, Preben B. AU - Ribasés, Marta AU - Børglum, Anders D. AU - Demontis, Ditte TI - Differences in the genetic architecture of common and rare variants in childhood, persistent and late-diagnosed attention deficit hyperactivity disorder AID - 10.1101/2021.08.06.21261679 DP - 2021 Jan 01 TA - medRxiv PG - 2021.08.06.21261679 4099 - http://medrxiv.org/content/early/2021/08/08/2021.08.06.21261679.short 4100 - http://medrxiv.org/content/early/2021/08/08/2021.08.06.21261679.full AB - Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder, with onset in childhood (“childhood ADHD”), and around two thirds of affected individuals will continue to have ADHD symptoms in adulthood (“persistent ADHD”). Age at first diagnosis can vary, and sometimes ADHD is first diagnosed in adulthood (“late-diagnosed ADHD”).In this study, we analyzed a large Danish population-based case-cohort generated by iPSYCH in order to identify common genetic risk loci and perform in-depth characterization of the polygenic architecture of childhood (N=14,878), persistent (N=1,473) and late-diagnosed ADHD (N=6,961) alongside 38,303 controls. Additionally, the burden of rare protein truncating variants in the three groups were evaluated in whole-exome sequencing data from a subset of the individuals (7,650 ADHD cases and 8,649 controls). We identified genome-wide significant loci associated with childhood ADHD (four loci) and late-diagnosed ADHD (one locus). In analyses of the polygenic architecture, we found higher polygenic score (PGS) of ADHD risk variants in persistent ADHD (mean PGS=0.41) compared to childhood (mean PGS=0.26) and late-diagnosed ADHD (mean PGS=0.27), and we found a significant decreased genetic correlation of late-diagnosed ADHD with inattention (rg=0.57) compared to childhood ADHD (rg=0.86). These results suggest that a higher ADHD polygenic risk burden is associated with persistence of symptoms, and that a later diagnosis of ADHD could be due in part to genetic factors. Additionally, childhood ADHD demonstrated both a significantly increased genetic overlap with autism compared to late-diagnosed ADHD as well as the highest burden of rare protein-truncating variants in highly constrained genes among ADHD subgroups (compared to controls: beta=0.13, P=2.41×10−11). Late-diagnosed ADHD demonstrated significantly larger genetic overlap with depression than childhood ADHD and no increased burden in rare protein-truncating variants (compared to controls: beta=0.06). Overall, our study finds genetic heterogeneity among ADHD subgroups and suggests that genetic factors influence time of first ADHD diagnosis, persistence of ADHD and comorbidity patterns in the sub-groups.Competing Interest StatementD.D has received speaker fee from Takeda; J.A.R.Q was on the speaker's bureau and/or acted as consultant for Janssen-Cilag, Novartis, Shire, Takeda, Bial, Shionogi, Sincrolab, Novartis, BMS, Medice, Rubiand Raffo in the last 3 years. He also received travel awards (air tickets + hotel) for taking part in psychiatric meetings from Janssen-Cilag, RubiShire, Takeda, Shionogi, Bial and Medice. The Department of Psychiatry chaired by him received unrestricted educational and research support from the following companies in the last 3 years: Janssen-Cilag, Shire, Oryzon, Roche, Psious, and RubiòFunding StatementThe iPSYCH team was supported by grants from the Lundbeck Foundation (R102-A9118, R155-2014-1724 and R248-2017-2003), the EU FP7 Program (Grant No. 602805, "Aggressotype") and H2020 Program (Grant No. 667302, "CoCA"), NIMH (1U01MH109514-01 to ADB) and the universities and university hospitals of Aarhus and Copenhagen. The Danish National Biobank resource was supported by the Novo Nordisk Foundation. High-performance computer capacity for handling and statistical analysis of iPSYCH data on the GenomeDK HPC facility was provided by the Center for Genomics and Personalized Medicine and the Centre for Integrative Sequencing, iSEQ, Aarhus University, Denmark (grant to ADB). M.S.A. is a recipient of a Juan de la Cierva Incorporacion contract from the Ministry of Science, Innovation and Universities, Spain (IJC2018-035346-I). The research leading to these results has received funding from the Instituto de Salud Carlos III (PI17/00289, PI18/01788, P19/01224 and PI20/00041) and from the Agencia de Gestio d'Ajuts Universitaris i de Recerca-AGAUR, Generalitat de Catalunya (2017SGR1461) and cofinanced by the European Regional Development Fund (ERDF). The Norwegian Mother, Father and Child Cohort Study is supported by the Norwegian Ministry of Health and Care Services and the Ministry of Education and Research. We are grateful to all the participating families in Norway who take part in this on-going cohort study. L.V.R. is a recipient of a pre-doctoral fellowship from the Instituto de Salud Carlos III, Spain (FI18/00285). M.R. was a recipient of a Miguel de Servet contract from the Instituto de Salud Carlos III, Spain (CP09/00119 and CPII15/00023). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Danish Scientific Ethics Committee, the Danish Health Data Authority, the Danish data protection agency, the Danish Neonatal Screening Biobank steering committee and Statistics Denmark, approved this study. The requirement of multiple permissions is in keeping with the ethical framework and the Danish legislation protecting the use of these samples.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSummary statistics from GWAS of childhood, persistent and late-diagnosed ADHD is available at the iPSYCH website (https://ipsych.dk/en/research/downloads/)